CRTX - Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
- COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
- COR388, the first-generation lysine gingipain inhibitor, didn't achieve statistical significance in the entire Alzheimer's population, but did well in a prespecified group of patients with P. gingivalis.
- The global market opportunity for Alzheimer's Disease could reach $17.7 billion by 2025.
- COR388 is not being used towards Alzheimer's Disease, but Cortexyme is still developing it against other P. gingivalis diseases like periodontal disease and oral/head and neck squamous cell carcinoma.
For further details see:
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment